M&A Deal Summary |
|
|---|---|
| Date | 2018-04-17 |
| Target | Zentiva |
| Sector | Life Science |
| Buyer(s) | Advent International |
| Sellers(s) | Sanofi |
| Deal Type | Divestiture |
| Deal Value | 1.9B EUR |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 1984 |
| PE ASSETS | 76.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
Advent is a global private equity firm that targets investments in North America, Europe, Asia, and Latin America. Advent's emerging market efforts are concentrated in Central Europe and Latin America. Advent seeks transactions valued between $50 million and $5 billion and can commit up to $2 billion of equity capital per investment. Broad areas of interest include business & financial services, retail & consumer, technology, media, & telecoms, healthcare & life sciences, and industrial. Prospective transaction types include buyouts, growth capital financings, take privates, and recapitalizations. Advent was formed in 1984 and is based in Boston, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 259 of 330 |
| Sector (Life Science) | 12 of 20 |
| Type (Divestiture) | 19 of 37 |
| Country (Czech Republic) | 6 of 6 |
| Year (2018) | 6 of 10 |
| Size (of disclosed) | 14 of 47 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-03-30 |
Clearent
Creve Coeur, Missouri, United States Clearent is a provider of full-service, payment solutions that leverages its proprietary payments platform to make doing business easier and more profitable for its sales partners. Clearent was founded in 2005 and is based in Creve Coeur, Missouri. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-05-07 |
MORSCO
Forth Worth, Texas, United States MORSCO, Inc. is a wholesale distributor of plumbing, HVAC, and builder products in the Southwest. Sovos Brands is a new kind of food and beverage company with a mission to acquire and build one-of-a-kind brands. Its portfolio includes Michael Angelo’s Gourmet Foods, a leading producer of premium, authentic frozen Italian entrées, and Rao’s Specialty Foods, a producer of super premium pasta sauce and other Italian specialty foods. Founded in 1917, Morrison now operates approximately eighty locations in Texas, New Mexico, Oklahoma, Kansas, and Louisiana. |
Sell | $1.4B |
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Life Science |
| Employees | 99,412 |
| Revenue | 45.4B EUR (2022) |
Sanofi is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi was founded in 1994 and is based in Paris, France.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 14 |
| Sector (Life Science) | 6 of 8 |
| Type (Divestiture) | 8 of 14 |
| Country (Czech Republic) | 1 of 1 |
| Year (2018) | 2 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-02-01 |
Sanofi SA - Leukine
Paris, France Sanofi SA - Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body's immune response to fight infections. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-06-18 |
Sanofi SA - Infectious diseases
Paris, France Sanofi SA - Infectious diseases are caused by bacteria, viruses, fungi or parasites and can be spread, directly or indirectly, from one person to another. Treatments for infectious diseases include antibiotics and anti-viral medications. Today, infectious diseases propagated by bacteria are becoming increasingly resistant to many antibiotics and any use of antibiotics reduces the effectiveness of these drugs for other patients. The World Health Organization (“WHO”) has deemed antibiotic resistance to be one of the three greatest threats to human health today. Almost a million people die of resistant infections a year. It is also estimated that by 2050, 10 million lives a year and a cumulative 100 trillion dollars of economic output are at risk due to the rise of drug resistant infections, if solutions to this problem are not identified now. Thus, there is a critical need to research and develop medical solutions to combat antibiotic resistant bacteria. |
Sell | - |
